Coupled with selection for biomarkers specific to sarcoma subtypes such as TLE1 or ASPL-TFE3, the ApoStream® device will facilitate CTC isolation and analysis for anticancer drug development, longitudinal monitoring of pharmacodynamic drug effects, and disease management for patients with carcinoma or sarcoma alike. This evidence concerns the gene TLE1 and sarcoma.